全文获取类型
收费全文 | 35174篇 |
免费 | 2765篇 |
国内免费 | 348篇 |
专业分类
耳鼻咽喉 | 385篇 |
儿科学 | 976篇 |
妇产科学 | 954篇 |
基础医学 | 4482篇 |
口腔科学 | 588篇 |
临床医学 | 3626篇 |
内科学 | 7467篇 |
皮肤病学 | 827篇 |
神经病学 | 2360篇 |
特种医学 | 1306篇 |
外科学 | 4836篇 |
综合类 | 1149篇 |
一般理论 | 32篇 |
预防医学 | 1869篇 |
眼科学 | 1559篇 |
药学 | 2692篇 |
2篇 | |
中国医学 | 306篇 |
肿瘤学 | 2871篇 |
出版年
2023年 | 239篇 |
2022年 | 178篇 |
2021年 | 717篇 |
2020年 | 600篇 |
2019年 | 753篇 |
2018年 | 980篇 |
2017年 | 760篇 |
2016年 | 854篇 |
2015年 | 1036篇 |
2014年 | 1368篇 |
2013年 | 1635篇 |
2012年 | 2340篇 |
2011年 | 2451篇 |
2010年 | 1408篇 |
2009年 | 1238篇 |
2008年 | 1912篇 |
2007年 | 2005篇 |
2006年 | 1991篇 |
2005年 | 1925篇 |
2004年 | 1701篇 |
2003年 | 1584篇 |
2002年 | 1419篇 |
2001年 | 1112篇 |
2000年 | 1050篇 |
1999年 | 890篇 |
1998年 | 343篇 |
1997年 | 250篇 |
1996年 | 234篇 |
1995年 | 215篇 |
1994年 | 208篇 |
1993年 | 209篇 |
1992年 | 457篇 |
1991年 | 444篇 |
1990年 | 426篇 |
1989年 | 425篇 |
1988年 | 363篇 |
1987年 | 391篇 |
1986年 | 336篇 |
1985年 | 299篇 |
1984年 | 215篇 |
1983年 | 157篇 |
1982年 | 99篇 |
1981年 | 93篇 |
1980年 | 100篇 |
1979年 | 142篇 |
1978年 | 92篇 |
1977年 | 84篇 |
1976年 | 83篇 |
1975年 | 77篇 |
1972年 | 69篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Ding Fangfang Huang Jie Feng Zeying Kuang Yun Yang Shuang Xiang Yuxia Zou Chan Yang Guoping 《Investigational new drugs》2022,40(3):606-613
Investigational New Drugs - Purpose. This study aimed to compare the safety, tolerability, pharmacokinetics (PK), and bioequivalence of a test humanized recombinant monoclonal antibody targeting... 相似文献
3.
Ma Junlong Chen Wenjing Hu Zhanqing Huang Jie Guo Chengxian Zou Chan Yang Guoping 《Investigational new drugs》2022,40(4):861-867
Investigational New Drugs - Pertuzumab is a recombinant anti-HER2 humanized monoclonal antibody widely used for the adjuvant treatment of HER2-positive breast cancer. Its safety is well established... 相似文献
4.
Robert S. Dean Brian R. Waterman Amanda J. Naylor Shelby A. Sumner William Chan Anthony A. Romeo Gregory P. Nicholson 《Seminars in Arthroplasty》2022,32(2):272-278
BackgroundThe purpose of this study is to determine the comparative risk profile and clinical outcomes for patients undergoing reverse total shoulder arthroplasty (RTSA) for cuff tear arthropathy (CTA) without failed prior rotator cuff repair (RCR) compared with RTSA for CTA with prior RCR.MethodsFrom 2006 to 2014, all patients who underwent RTSA by two surgeons after failed RCR with minimum 2-year follow-up were identified. Patients who underwent RTSA with failed prior RCR were matched in a 1:1 ratio to patients undergoing primary RTSA, while controlling for demographic factors, prosthesis design, and surgeon. Postoperative active forward elevation and active external rotation were recorded. Outcome measures included American Shoulder and Elbow Surgeons score, Visual Analog Scale (VAS), and Simple Shoulder Test. Perioperative complications and rates of secondary reoperation were noted, and comparative multivariate analysis was performed.ResultsOf 262 patients, 192 (73.3%) were available at minimum 2-year follow-up. The prior RCR group had a significantly higher complication rate (17.4%, n = 15) than the primary RTSA group (3.8%, n = 4) (P = .001), although no significant difference in periprosthetic infection (P = .469) or secondary revision rate (P = .136) was observed. At mean 36.3 ± 26.1-month follow-up, the prior RCR group had statistically worse American Shoulder and Elbow Surgeons score (P < .001), VAS (P = .001), Simple Shoulder Test (P < .001), and active forward elevation (P = .006). Patients with multiple failed RCR attempts (n = 38) before RTSA demonstrated no significant differences versus isolated failed RCR (n = 48; P > .05).ConclusionThis study demonstrated that patients with RTSA after prior failed RCR have significantly worse patient-reported outcomes and greater rate of perioperative complications than patients undergoing primary RTSA for CTA. 相似文献
5.
6.
7.
8.
Chamberlain Robert Edwards Natalie F. A. Scalia Gregory M. Chan Jonathan 《The international journal of cardiovascular imaging》2022,38(5):1077-1088
The International Journal of Cardiovascular Imaging - Early detection of acute cellular rejection (ACR) by echocardiography shows potential clinical benefit as ACR remains a significant contributor... 相似文献
9.
Dongbing Lai Emma C. Johnson Sarah Colbert Gayathri Pandey Grace Chan Lance Bauer Meredith W. Francis Victor Hesselbrock Chella Kamarajan John Kramer Weipeng Kuang Sally Kuo Samuel Kuperman Yunlong Liu Vivia McCutcheon Zhiping Pang Martin H. Plawecki Marc Schuckit Jay Tischfield Leah Wetherill Yong Zang Howard J. Edenberg Bernice Porjesz Arpana Agrawal Tatiana Foroud 《Alcoholism, clinical and experimental research》2022,46(3):374-383
10.
Raymond J. Chan RN PhD Vivienne E. Milch MBBS MHPol Fiona Crawford-Williams PhD Oluwaseyifunmi Andi Agbejule BRadTherapy Ria Joseph MNutrDiet Jolyn Johal BND Narayanee Dick BSc Matthew P. Wallen PhD Julie Ratcliffe PhD Anupriya Agarwal MBBS Larissa Nekhlyudov MD Matthew Tieu PhD Manaf Al-Momani BPharm Scott Turnbull PhD Rahul Sathiaraj MPH Dorothy Keefe MBBS MD Nicolas H. Hart PhD 《CA: a cancer journal for clinicians》2023,73(6):565-589
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs. 相似文献